Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: Final results of the ARIES observational cohort study

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages 1332-1339

  Lynch, Thomas J ^a   Spigel, David R ^b   Brahmer, Julie ^c   Fischbach, Neal ^d   Garst, Jennifer ^e   Jahanzeb, Mohammad ^f   Kumar, Priya ^g   Vidaver, Regina M ^h   Wozniak, Antoinette J ⁱ   Fish, Susan ^j   Flick, E Dawn ^j   Leon, Larry ^j   Hazard, Sebastien J ^j   Kosty, Michael P ^k  

^a YALE CANCER CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PC   (United States)

^e DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^f UNIVERSITY OF MIAMI   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h National Lung Cancer Partnership   (United States)

ⁱ KARMANOS CANCER INSTITUTE   (United States)

^j GENENTECH INC   (United States)

^k SCRIPPS CLINIC   (United States)

more..

Author keywords

Bevacizumab; Chemotherapy; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; PLACEBO; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHYSICIAN; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; EPIDEMIOLOGY; EUROPE; FOLLOW UP; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL RATE; TIME; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84906242661     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000257     Document Type: Article

References (13)

1. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology - Non-Small Cell Lung Cancer, version 2.2013. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines. asp. Accessed December 19, 2013.
2. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
3. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-718.
4. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234.
5. Reck M, von Pawel J, Zatloukal P, et al.; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as firstline therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-1809.
6. Gridelli C, Maione P, Rossi A, et al. Treatment of advanced non-smallcell lung cancer in the elderly. Lung Cancer 2009;66:282-286.
7. Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-smallcell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010;11:733-740.
8. Laskin J, Crinò L, Felip E, et al. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer. J Thorac Oncol 2012;7:203-2011.
9. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-1218.
10. Grootendorst DC, Jager KJ, Zoccali C, et al. Observational cohort studies are complementary to randomized controlled trials. Nephron Clin Pract 2010;114:c173-c177.
11. Ritzwoller DP, Carroll NM, Delate T, et al. Patterns and predictors of chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network. Lung Cancer 2012;78:245-252.
12. Kozloff M, Yood MU, Berlin J, et al.; Investigators of the BRiTE Study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009;14:862-870.
13. Thadhani R, Tonelli M. Cohort studies: marching forward. Clin J Am Soc Nephrol 2006;1:1117-1123.